Up Services INC

Up Services INC was paid $3.94M by Medicaid between Jan 2018 and Nov 2024, across 194 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 23% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#16 of 225

Median peer was paid$74K

This provider vs. median54×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	6,887	$738K
2019	34,088	$234K
2020	39,507	$710K
2021	53,695	$800K
2022	48,724	$723K
2023	56,549	$407K
2024incomplete	38,894	$331K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	23%	9,251	8,190	$922K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	18%	12,327	9,393	$716K
87631		6.9%	5,183	4,194	$272K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.3%	9,287	6,966	$168K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	2.9%	6,874	6,595	$113K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.6%	5,087	4,171	$101K
88120		2.1%	882	835	$83K
87486		1.7%	4,720	3,885	$66K
87581		1.7%	4,719	3,884	$66K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.5%	2,706	2,217	$57K
86769		1.3%	1,850	1,833	$52K
82607		1.2%	6,626	6,362	$47K

182 more codes

81162		1.2%	36	$46K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,462	$38K
83970		<1%	1,466	$38K
84403		<1%	2,280	$35K
80053	Comprehensive metabolic panel	<1%	7,670	$35K
83036	Hemoglobin; glycosylated (A1C)	<1%	6,865	$33K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	1,300	$33K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	2,330	$33K
82746		<1%	5,150	$32K
81408		<1%	79	$30K
82728		<1%	4,360	$29K
84481		<1%	5,884	$29K
86141		<1%	4,904	$29K
80061	Lipid panel	<1%	8,849	$28K
84439		<1%	6,214	$27K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	9,620	$26K
86328		<1%	674	$26K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	3,083	$23K
84153		<1%	2,223	$22K
84443	Thyroid stimulating hormone (TSH)	<1%	5,273	$22K
80050	General health panel	<1%	2,433	$21K
82784		<1%	2,050	$17K
86803		<1%	3,139	$17K
83090		<1%	1,673	$17K
86481		<1%	512	$16K
86703		<1%	1,766	$16K
88108		<1%	1,447	$16K
81201		<1%	79	$15K
81292		<1%	79	$14K
86160		<1%	1,129	$13K
87340		<1%	2,308	$13K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	7,935	$13K
81317		<1%	79	$13K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	202	$13K
81298		<1%	94	$13K
83001		<1%	1,136	$13K
84402		<1%	772	$12K
83002		<1%	1,039	$12K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	625	$12K
81321		<1%	78	$11K
84165		<1%	2,434	$11K
81000		<1%	6,275	$11K
86708		<1%	2,072	$11K
80177		<1%	1,803	$11K
88312		<1%	434	$11K
82670		<1%	606	$11K
81404		<1%	79	$10K
87481		<1%	362	$10K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	2,114	$10K
84550		<1%	3,955	$9K
86704		<1%	1,865	$9K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	584	$8K
81405		<1%	66	$8K
81295		<1%	94	$7K
86003		<1%	311	$7K
81406		<1%	79	$7K
84270		<1%	1,683	$7K
82785		<1%	1,065	$7K
83735		<1%	2,245	$7K
86235		<1%	1,121	$7K
82570		<1%	2,158	$6K
86376		<1%	674	$6K
83540		<1%	2,423	$6K
86317		<1%	1,787	$6K
88112		<1%	264	$6K
80345		<1%	2,763	$5K
84144		<1%	375	$5K
80353		<1%	1,849	$5K
84100		<1%	1,910	$5K
80335		<1%	1,854	$5K
83550		<1%	2,161	$5K
82977		<1%	1,934	$5K
80356		<1%	1,748	$5K
86431		<1%	1,613	$5K
84146		<1%	357	$5K
86800		<1%	551	$5K
86038		<1%	1,449	$5K
82550		<1%	1,568	$4K
83615		<1%	1,531	$4K
82533		<1%	363	$4K
86200		<1%	956	$4K
82627		<1%	296	$4K
80329		<1%	1,029	$4K
86706		<1%	797	$4K
85651		<1%	3,054	$4K
81403		<1%	80	$4K
87086	Culture, bacterial; quantitative colony count, urine	<1%	838	$3K
86592		<1%	1,445	$3K
81401		<1%	162	$3K
86618		<1%	178	$3K
88237		<1%	95	$3K
86735		<1%	793	$3K
87500		<1%	227	$3K
86762		<1%	410	$3K
84480		<1%	6,164	$2K
86765		<1%	427	$2K
80361		<1%	1,849	$2K
87430		<1%	515	$2K
80346		<1%	1,744	$2K
80324		<1%	1,860	$2K
81211		<1%	43	$2K
82043		<1%	671	$2K
83690		<1%	460	$2K
87653		<1%	226	$2K
84681		<1%	92	$1K
85044		<1%	1,326	$1K
82378		<1%	115	$1K
84445		<1%	36	$1K
88311		<1%	308	$1K
86787		<1%	327	$1K
86695		<1%	656	$1K
87640		<1%	181	$925.58
87641		<1%	76	$924.33
80375		<1%	1,043	$914.42
80184		<1%	1,901	$856.30
80369		<1%	1,726	$848.19
84446		<1%	99	$799.44
86780		<1%	95	$740.79
87563		<1%	47	$669.37
83520		<1%	123	$667.19
85610		<1%	346	$661.70
84590		<1%	98	$645.58
83525		<1%	106	$639.11
83992		<1%	1,052	$623.39
83785		<1%	41	$596.11
82150		<1%	272	$535.00
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	21	$462.15
80321		<1%	1,042	$445.82
80354		<1%	1,041	$430.37
80359		<1%	668	$394.72
82300		<1%	41	$356.94
84479		<1%	179	$313.02
84305		<1%	37	$301.73
84425		<1%	36	$301.73
84436		<1%	161	$297.52
85730		<1%	140	$288.02
84133		<1%	77	$262.95
84466		<1%	34	$250.36
84207		<1%	14	$241.66
82180		<1%	42	$231.02
81241		<1%	72	$220.11
84300		<1%	58	$214.70
81227		<1%	70	$212.10
81240		<1%	72	$197.07
84255		<1%	45	$196.97
82108		<1%	16	$195.80
83020		<1%	33	$195.58
84630		<1%	40	$173.61
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	362	$172.63
83018		<1%	43	$169.37
82105		<1%	45	$153.54
83825		<1%	12	$147.74
86480		<1%	39	$142.93
83655		<1%	14	$115.15
84154		<1%	13	$110.34
83986		<1%	1,180	$106.50
84152		<1%	12	$90.84
84702		<1%	12	$89.88
84252		<1%	15	$84.85
88313		<1%	17	$83.55
82652		<1%	13	$48.44
80048	Basic metabolic panel (calcium, ionized)	<1%	12	$24.81
86140		<1%	22	$15.27
82248		<1%	14	$10.71
81293		0%	54	$0.00
80051		0%	98	$0.00
81225		0%	72	$0.00
81351		0%	48	$0.00
36415	Collection of venous blood by venipuncture	0%	14	$0.00
81231		0%	70	$0.00
81226		0%	69	$0.00
81230		0%	70	$0.00
81168		0%	17	$0.00
81212		0%	14	$0.00
81291		0%	65	$0.00
81328		0%	70	$0.00
81339		0%	14	$0.00
81164		0%	23	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	28	$0.00
83721		0%	16	$0.00
81213		0%	42	$0.00
81163		0%	23	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialABRAZI, BELLA (CEO)

Same official

Other billing entities under ABRAZI, BELLA

Full network →

Provider	Location	Paid
Enigma Management Corp Dba Alliance Laboratory	Brooklyn, NY	$3.85M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.